VNDA
Vanda Pharmaceuticals Inc. · Healthcare
7.45
6.89%(+0.48)
Prev. Close7.69
3.22%(+0.24)
Pre-marketLast Updated: — ET
52W L: $3.8152W H: $9.94
$7.49
CHG-0.31 (-4.00%)
H$10.24
L$6.57
VOL33M
VNDA (1h)
Vanda Pharmaceuticals Inc. · Healthcare
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.51 and traded as high as $7.04. Vanda Pharmaceuticals shares last traded at $6.97, with a volume of 768,496 shares traded. Wall Street Analysts Forecast Growth
WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug Administration (FDA)'s new draft guidance, "General Considerations for the Use of New Approach Methodologies in Drug Development," released March 18, 2026, by the Center for Drug Evaluation and Research (CDER). The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs)—advanced non-animal tools like in vitro assays, organ-on-chip systems, computational models, and human cell-based platforms—to modernize nonclinical testing and move away from traditional animal models.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation
WASHINGTON, March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review the Center for Drug Evaluation and Research's (CDER) proposal to refuse approval of Vanda's supplemental new drug application (sNDA) for HETLIOZ® (tasimelteon) in the treatment of jet lag disorder. The FDA confirmed the decision to grant a hearing in a letter from the Office of the Commissioner dated March 2, 2026.
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m.
Vanda Pharmaceuticals (NASDAQ: VNDA) shares are up during Wednesday's premarket session following the FDA's approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, as well as the company's rare skin disease drug is under FDA review.
Williams Timothy
officer: SVP & General Counsel
42,434 SH @ $8.27
2026-03-02
Moran Kevin Patrick
officer: SVP, CFO & Treasurer
42,442 SH @ $8.27
2026-03-02
Wijkstrom Joakim
officer: SVP, Chief Marketing Officer
30,800 SH @ $8.27
2026-03-02
Polymeropoulos Mihael Hristos
director, officer, other: President and CEO
156,235 SH @ $8.17
2026-03-02
Birznieks Gunther
officer: SVP, Business Development
42,431 SH @ $8.27
2026-03-02
Honore Tage
director
30,000 SH @ $8.03
2026-02-23
Wijkstrom Joakim
officer: SVP, Chief Marketing Officer
125,000 SH @ $0.00
2026-02-18
Birznieks Gunther
officer: SVP, Business Development
125,000 SH @ $0.00
2026-02-18